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ABSTRACT
Background: Constant increase of erythromycin and clindamycin resistance has been 
observed worldwide among group B streptococcal (GBS) isolates. In Belgium, through 
the 2000s, erythromycin resistance has increased from 20% to up to 30%. Therefore 
phenotypical and molecular surveillance of erythromycin and clindamycin resistance 
patterns has been conducted.
Materials and Methods: A total of 328 GBS isolates, previously serotyped by PCR, 
were collected:  275 clinical isolates (N1) were obtained from the Belgian surveillance 
for invasive GBS disease in newborns (59 isolates from 32 early- and 27 late-onset 
diseases) and adults (216 isolates) during 2008 to 2011 and 53 isolates (N2) from 
recto-vaginal colonization among pregnant women in 2010. Erythromycin and 
clindamycin MICs were determined by using Etest® (EUCAST interpretative 
criteria). Furthermore, for the erythromycin-resistant isolates, the inducible (iMLS), 
constitutive (cMLS) and M phenotypes were assessed by a double-disk diffusion test; 
the distribution of genes encoding RNA methylases (erm) and efflux pumps (mef) was 
investigated by PCR.
Results: Of the N1 and N2 isolates, 94 (34,2%) and 15 (28,3%) were respectively 
resistant to erythromycin. Among these 109 isolates, 102 (93,6%) exhibited the MLS 
phenotype (resistant to erythromycin and clindamycin): 74 were cMLS with 
erythromycin MIC50 ≥256 mg/L and 28 iMLS with erythromycin MIC50/90 16/≥256 
mg/L. The M phenotype (resistant to erythromycin and susceptible to clindamycin) 
was expressed by 7 (6,4%) of the isolates with erythromycin MIC50/90 4/12 mg/L. One 
isolate presented a newly described resistance mechanism in GBS: the L phenotype 
(susceptible to erythromycin and resistant to clindamycin) with a clindamycin MIC of 
8 mg/L.
For cMLS, the most common genotype was ermB (65%) (P <0,05) followed by ermTR
(30%) and ermB+ermTR (5%). All iMLS isolates harbored an ermTR gene except 3 (2 
with ermB, 1 with both ermB and ermTR); and all M phenotypes were positive for 
mefA/B gene.
Conclusion: 1) In Belgium, by year 2010, prevalence of macrolide resistance in GBS 
exceed 30%, with a significant higher rate among serotype V (P <0,001) and serotype 
IV (P < 0,01).  2) Resistance mechanisms were mainly MLS phenotypes (target-site 
modification); M phenotype (efflux resistance mechanism) was also prevalent.            
3) Resistance surveillance is mandatory to guide prophylaxis and treatment of serious 
GBS infections but also to identify newly acquired resistance mechanisms such as the 
L phenotype.
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INTRODUCTION
Resistance to macrolides and lincosamides has increased worldwide 
among  group B  streptococcal (GBS) isolates over the last two 
decades: from less than 5% to common resistance of 20% to 30%. 
Different known mechanisms account for acquired resistance to 
macrolides in streptococci. The most prevalent of these is target site 
modification by 23S rRNA methylases, commonly encoded by the 
ermB and ermA subclass ermTR genes. The Erm enzymes confer 
resistance to macrolides and inducible or constitutive resistance to 
lincosamides and streptogramin B, so-called MLSB phenotype. 
Another mechanism, involving active drug efflux, is encoded by the 
mefA and mefE genes; the Mef pump affects 14- and 15- membered
ring macrolides but not 16-membered macrolides, neither 
lincosamides nor streptogramin B (M phenotype). Apart from these 
worrying resistances, a other phenotype involving low-level of 
clindamycin resistance (with erythromycin remaining susceptible) in 
GBS isolates has recently been reported in many countries: the L
phenotype.
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AIM
To determine the phenotypical and molecular  resistance 
patterns for erythromycin- and clindamycin-resistant 
group B streptococcus  and to identify the resistance 
genes (ermB, ermTR and mefA/B) among  erythromycin-
resistant S. agalactiae isolated in Belgium from various 
clinical and colonizing origins.
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MATERIALS AND METHODS
Strains
Determination of erythromycin and clindamycin MICs
• Etest® method (AB Biodisk®, Sweden)
• Inoculum 0,5 McFarland on Mueller-Hinton agar +5% sheep blood
• Incubation 18h at 35°C
• MIC resistance breakpoints: > 0,5 mg/L, EUCAST 2011
Determination of  erythromycin resistance phenotypes
• Double-disk diffusion assay
• Erythromycin 15 µg paper-disks and clindamycin 2 µg paper disks  (Becton 
Dickinson and Company®, USA) 
• Disks placed 15-20 mm apart on agar plate; 18-24h incubation at 35°C
• MLSB phenotype:
• Inducible resistance (iMLS): blunting of the clindamycin zone of inhibition 
proximal to the erythromycin disk, or D-Shape
• Constitutive resistance (cMLS): resistance to clindamycin with no blunting of 
the clindamycin zones of inhibition
• M phenotype: susceptibility to clindamycin with no blunting of the clindamycin
zones of inhibition
Identification of resistance genes
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Description of 328 non-redundant GBS strains from which erythromycin and/or 





Summary of PCR 
protocols using 
specific primers for 
known macrolide-
resistance markers 
and for dltS gene
RESULTS
Erythromycin and clindamycin resistance rates
Among the 328 clinical and colonizing GBS collected between 2008 and 2011, 109/328 
isolates (33,2%) and 75/328 isolates (22,9%) were resistant to erythromycin and 
clindamycin respectively. Rate of resistance to clindamycin was higher when inducible 
resistance (iMLS) was added to cMLS and L phenotypes: 103/328 (31,4%). 
Distribution of resistance phenotypes and genotypes
Evolution macrolide and lincosamide resistance in GBS
in Belgium between 2000 and 2010 (3)









Genotypical distribution of 109 erythromycin-resistant GBS isolated from adult 
infections, neonatal infections (EOD and LOD) and colonization in pregnant 
women
RESULTS
Correlation of erythromycin MICs with genotypes





MIC50 ≥256 mg/L 64 mg/L ≥256 mg/L 4 mg/L
MIC90 ≥256 mg/L ≥256 mg/L ≥256 mg/L 12 mg/L
CONCLUSIONS
 In Belgium, by the year 2010, prevalence of macrolide and 
lincosamide resistance among GBS exceeded 30%.
 Erythromycin resistance was higher among GBS isolated from adult
invasive infections than from neonatal population.
 MLS phenotypes, either constitutive or inducible, were predominant 
leading to cross-resistance to macrolides and lincosamides. These isolates 
harbored a target-site modification gene: ermB or ermTR, or both.
 Efflux resistance mechanism (M phenotype), also prevalent among 
GBS isolates, was always encoded by mefA/B gene.
 Erythromycin MICs were well correlated with genotypes. High level of 
erythromycin-resistance was associated with ermB isolates while low level 
of resistance was present in mefA/B isolates.
 The highest proportion of MLS phenotypes (cMLS and iMLS) and the 
emergence of L phenotype could explain the recent increase in clindamycin
resistance rate.
 Constant increase of macrolide and lincosamide resistance rates 
stresses the importance of performing susceptibility testing for GBS 
isolates issued from prenatal screening in women who are at high risk for 
penicillin anaphylaxis, where clindamycin is the recommended antibiotic 
alternative.
 Resistance surveillance is mandatory to guide prophylaxis and 
treatment of serious GBS infections but also to identify newly acquired 
resistance mechanisms such as the L phenotype.
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•Thermocycler: Thermo Hybaid Hbpxe 02® thermocycler (Thermo Scientific®, USA)
•Following amplification, the products were visualized by electrophotesis on 2% 
agarose gel by ethidium bromide staining
